ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

被引：0
|
作者：
Susanna Slater
Annette Bryant
Hsiang-Chi Chen
Ruwaida Begum
Isma Rana
Maria Aresu
Clare Peckitt
Oleg Zhitkov
Retchel Lazaro-Alcausi
Victoria Borja
Rachel Powell
David Lowery
Michael Hubank
Thereasa Rich
Gayathri Anandappa
Ian Chau
Naureen Starling
David Cunningham
机构：
[1] Royal Marsden Hospital NHS Foundation Trust,
[2] Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research,undefined
[3] Centre for Molecular Pathology at the The Royal Marsden Hospital and Institute of Cancer Research,undefined
[4] Guardant Health,undefined
[5] INC,undefined
来源：
BMC Cancer | / 23卷
关键词：
Colorectal cancer; ctDNA; Adjuvant chemotherapy; Randomised; Disease free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 47 条
  • [1] ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
    Slater, Susanna
    Bryant, Annette
    Chen, Hsiang-Chi
    Begum, Ruwaida
    Rana, Isma
    Aresu, Maria
    Peckitt, Clare
    Zhitkov, Oleg
    Lazaro-Alcausi, Retchel
    Borja, Victoria
    Powell, Rachel
    Lowery, David
    Hubank, Michael
    Rich, Thereasa
    Anandappa, Gayathri
    Chau, Ian
    Starling, Naureen
    Cunningham, David
    BMC CANCER, 2023, 23 (01)
  • [2] Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
    Lee, Yujin
    Park, Inseok
    Cho, Hyunjin
    Gwak, Geumhee
    Yang, Keunho
    Bae, Byung-Noe
    ANNALS OF COLOPROCTOLOGY, 2021, 37 (05) : 298 - 305
  • [3] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    H Samonigg
    R Schaberl-Moser
    R Greil
    R Thödtmann
    J Tschmelitsch
    M Jagoditsch
    G G Steger
    R Jakesz
    F Herbst
    F Hofbauer
    H Rabl
    P Wohlmuth
    M Gnant
    J Thaler
    British Journal of Cancer, 2007, 97 : 1021 - 1027
  • [4] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Schaberl-Moser, R.
    Greil, R.
    Thoedtmann, R.
    Tschmelitsch, J.
    Jagoditsch, M.
    Steger, G. G.
    Jakesz, R.
    Herbst, F.
    Hofbauer, F.
    Rabl, H.
    Wohlmuth, P.
    Gnant, M.
    Thaler, J.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1021 - 1027
  • [5] Survival paradox and effect of adjuvant chemotherapy for high-risk Stage II and low-risk Stage III colorectal cancer
    Noda, Keisuke
    Tominaga, Tetsuro
    Nonaka, Takashi
    Ono, Rika
    Oishi, Kaido
    Takamura, Yuma
    Shiraishi, Toshio
    Hashimoto, Shintaro
    Hisanaga, Makoto
    Takeshita, Hiroaki
    Ishii, Mitsutoshi
    Oyama, Shosaburo
    Ishimaru, Kazuhide
    Sawai, Terumitsu
    Matsumoto, Keitaro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 1183 - 1192
  • [6] Three timepoint perioperative CEA levels are a prognostic factor for recurrence after adjuvant chemotherapy in patients with Stage II and III colorectal cancer
    Mizuno, Shodai
    Shigeta, Kohei
    Hara, Ryosuke
    Sakamoto, Kyoko
    Nakadai, Jumpei
    Baba, Hideo
    Kikuchi, Hiroto
    Adachi, Yoko
    Shimada, Takehiro
    Suzumura, Hirofumi
    Sugiura, Kiyoaki
    Matsui, Shimpei
    Seishima, Ryo
    Okabayashi, Koji
    Kitagawa, Yuko
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024,
  • [7] Adjuvant Chemotherapy Use and Outcomes of Patients With High-Risk Versus Low-Risk Stage II Colon Cancer
    Kumar, Aalok
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    CANCER, 2015, 121 (04) : 527 - 534
  • [8] Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy
    Liang, Lei
    Zhu, Ji
    Jia, Huixun
    Huang, Liyong
    Li, Dawei
    Li, Qingguo
    Li, Xinxiang
    ONCOTARGET, 2016, 7 (01) : 1014 - 1028
  • [9] A Prognostic Nomogram and Heat Map to Predict Survival in Stage II/III Gastric Cancer Patients After Curative Gastrectomy Followed by Adjuvant Chemotherapy
    Shi, Litong
    Wang, Zehua
    Wang, Lei
    Jia, Yongxu
    Li, Jing
    Qin, Yanru
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 287 - 301
  • [10] International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
    Novello, S.
    Torri, V
    Grohe, C.
    Kurz, S.
    Serke, M.
    Wehler, T.
    Meyer, A.
    Ladage, D.
    Geissler, M.
    Colantonio, I
    Cauchi, C.
    Stoelben, E.
    Ceribelli, A.
    Kropf-Sanchen, C.
    Valmadre, G.
    Borra, G.
    Schena, M.
    Morabito, A.
    Santo, A.
    Gregorc, V
    Chiari, R.
    Reck, M.
    Schmid-Bindert, G.
    Folprecht, G.
    Griesinger, F.
    Follador, A.
    Pedrazzoli, P.
    Bearz, A.
    Caffo, O.
    Dickgreber, N. J.
    Irtelli, L.
    Wiest, G.
    Monica, V
    Porcu, L.
    Manegold, C.
    Scagliotti, G., V
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 57 - 66
12345